MX2020007384A - Metodos para tratar la diabetes, la hepatitis y/o la enfermedad inflamatoria del higado. - Google Patents

Metodos para tratar la diabetes, la hepatitis y/o la enfermedad inflamatoria del higado.

Info

Publication number
MX2020007384A
MX2020007384A MX2020007384A MX2020007384A MX2020007384A MX 2020007384 A MX2020007384 A MX 2020007384A MX 2020007384 A MX2020007384 A MX 2020007384A MX 2020007384 A MX2020007384 A MX 2020007384A MX 2020007384 A MX2020007384 A MX 2020007384A
Authority
MX
Mexico
Prior art keywords
hepatitis
liver disease
methods
inflammatory liver
treating diabetes
Prior art date
Application number
MX2020007384A
Other languages
English (en)
Inventor
Michael A Lynes
Yu-Hua Tseng
Matthew D Lynes
Original Assignee
Univ Connecticut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Connecticut filed Critical Univ Connecticut
Publication of MX2020007384A publication Critical patent/MX2020007384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente descripción se describen usos del inhibidor de la metalotioneína humana extracelular (MT) para tratar un trastorno seleccionado del grupo que consiste en diabetes, prediabetes, tolerancia a la glucosa alterada, hepatitis y/o enfermedad inflamatoria del hígado, y composiciones que contienen MT humana extracelular.
MX2020007384A 2018-01-17 2019-01-17 Metodos para tratar la diabetes, la hepatitis y/o la enfermedad inflamatoria del higado. MX2020007384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862618332P 2018-01-17 2018-01-17
PCT/US2019/013934 WO2019143767A1 (en) 2018-01-17 2019-01-17 Methods for treating diabetes, hepatitis, and/or inflammatory liver disease

Publications (1)

Publication Number Publication Date
MX2020007384A true MX2020007384A (es) 2020-10-19

Family

ID=65324621

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007384A MX2020007384A (es) 2018-01-17 2019-01-17 Metodos para tratar la diabetes, la hepatitis y/o la enfermedad inflamatoria del higado.

Country Status (20)

Country Link
US (3) US11866488B2 (es)
EP (2) EP4596042A3 (es)
JP (2) JP7486423B2 (es)
KR (2) KR102937161B1 (es)
CN (2) CN120267797A (es)
AU (2) AU2019209491B2 (es)
BR (1) BR112020014346A2 (es)
CA (1) CA3088661A1 (es)
EA (1) EA202091533A1 (es)
ES (1) ES3033317T3 (es)
HR (1) HRP20250727T1 (es)
HU (1) HUE072418T2 (es)
IL (2) IL316486A (es)
MX (1) MX2020007384A (es)
PH (1) PH12020551076A1 (es)
PL (1) PL3740282T3 (es)
RS (1) RS66918B1 (es)
SG (1) SG11202006421RA (es)
SM (1) SMT202500233T1 (es)
WO (1) WO2019143767A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020186247A1 (en) 2019-03-13 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for promoting islet viability and enhancing insulin secretion
BR112022000705A2 (pt) 2019-07-15 2022-03-22 Univ Connecticut Anticorpos de metalotioneína e seu uso
CN110551726B (zh) * 2019-09-06 2021-04-09 上海市肺科医院 一种结核杆菌阿拉伯半乳聚糖适配子及其应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
KR102191405B1 (ko) * 2020-09-15 2020-12-16 주식회사 에이스바이오메드 간 질환 예방 또는 치료용 조성물
CN115317502B (zh) * 2021-12-21 2023-07-07 青岛市市立医院 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用
WO2025226837A1 (en) * 2024-04-24 2025-10-30 University Of Connecticut Anti-bacterial metallothionein antibodies and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030007973A1 (en) * 2001-06-22 2003-01-09 Lynes Michael A. Methods and compositions for manipulation of the immune response using anti-metallothionein antibody
US8658174B2 (en) 2005-07-27 2014-02-25 Qinghua Wang GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes
WO2011050052A2 (en) * 2009-10-20 2011-04-28 Georgia State University Research Foundation, Inc. Protein agent for diabetes treatment and beta cell imaging
KR20130065728A (ko) 2010-10-14 2013-06-19 임뮤나르 에이비 Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드
CA2840282C (en) * 2011-07-08 2018-11-13 Universiteit Gent Use of antagonists targeting metallothionein to treat intestinal inflammation
US20160215042A1 (en) * 2013-04-19 2016-07-28 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
TR201402685A1 (tr) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.
EP3149049B1 (en) * 2014-05-27 2022-10-26 The University Of Queensland Il-22 for use in treating metabolic disorders
US9487783B2 (en) * 2014-08-07 2016-11-08 Regulus Therapeutics Inc. Targeting microRNAs for metabolic disorders

Also Published As

Publication number Publication date
US11866488B2 (en) 2024-01-09
KR102937161B1 (ko) 2026-03-10
EP4596042A2 (en) 2025-08-06
JP2024028454A (ja) 2024-03-04
JP2021511296A (ja) 2021-05-06
US20200369757A1 (en) 2020-11-26
ES3033317T3 (en) 2025-08-01
KR20200110659A (ko) 2020-09-24
CN111801140B (zh) 2025-05-16
EP3740282B1 (en) 2025-03-26
SG11202006421RA (en) 2020-08-28
AU2022215285A1 (en) 2022-09-29
AU2019209491A1 (en) 2020-07-23
WO2019143767A1 (en) 2019-07-25
EP3740282A1 (en) 2020-11-25
KR20260042289A (ko) 2026-03-30
PH12020551076A1 (en) 2021-08-16
CN111801140A (zh) 2020-10-20
SMT202500233T1 (it) 2025-07-22
AU2022215285B2 (en) 2024-08-29
BR112020014346A2 (pt) 2020-12-08
IL276097B1 (en) 2024-12-01
HUE072418T2 (hu) 2025-11-28
EP4596042A3 (en) 2025-11-05
JP7486423B2 (ja) 2024-05-17
IL276097A (en) 2020-08-31
US20240025981A1 (en) 2024-01-25
US20240067710A1 (en) 2024-02-29
RS66918B1 (sr) 2025-07-31
EP3740282C0 (en) 2025-03-26
CN120267797A (zh) 2025-07-08
HRP20250727T1 (hr) 2025-10-24
IL316486A (en) 2024-12-01
EA202091533A1 (ru) 2020-11-16
PL3740282T3 (pl) 2025-07-21
CA3088661A1 (en) 2019-07-25
AU2019209491B2 (en) 2022-05-19
IL276097B2 (en) 2025-04-01
US12583916B2 (en) 2026-03-24

Similar Documents

Publication Publication Date Title
CO2021005987A2 (es) Compuestos de anillo fusionado
CL2021000387A1 (es) Compuestos de anillo fusionado
ECSP20021323A (es) Proteínas de unión condicionalmente activadas restringidas
PA8794201A1 (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
BR112022001191A2 (pt) Combinações fungicidas, misturas e composições e usos das mesmas
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
BR112019006876A2 (pt) anticorpos e composições anti-lag-3
BR112019010943A2 (pt) métodos para o tratamento do câncer compreendendo agentes de ligação a tigit
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
PH12020551076A1 (en) Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
MX2017014805A (es) Composiciones para el tratamiento de condiciones patologicas de calcificacion y sus metodos de uso.
BR112015022776A8 (pt) estruturas de sola e artigos de calçado contendo membros de entressola leves com elementos protetores
AR107529A1 (es) Compuestos, composiciones y métodos para la estratificación de pacientes de cáncer y su tratamiento
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
BR112018010564A2 (pt) composições farmacêuticas compreendendo levodopa amida e usos das mesmas
MX2017016681A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
BR112018011526A2 (pt) compostos policíclicos como inibidores da tirosina quinase de bruton
BR112016023872A2 (pt) composição de resina adequada para impressão e método de impressão com o uso da mesma
CL2016000379A1 (es) Composiciones y métodos terapéuticos para reducción acelerada de plagas
UY38520A (es) Anticuerpos anti-pmel17, sus conjugados, composiciones que los comprenden, polinucleótidos, métodos y usos relacionados a los mismos
CL2023003984A1 (es) Composiciones del agente de arni de la cinasa de repetición 2 rica en leucina
BR112018071601A2 (pt) métodos, composições e usos relacionados aos mesmos
MX2023003548A (es) Composiciones acuosas que comprenden complejo lupulo-metal.
AR117343A1 (es) AGENTES DE UNIÓN REVERSIBLE PARA ANTICUERPOS ANTI-FACTOR XI / XIa Y USOS DE LOS MISMOS
BR112018017349A2 (pt) estrutura de dentadura, dentadura, e, método para formar uma estrutura de dentadura